| Internal medicine | 1 | The Effectiveness of Montelukast on Atopic Dermatitis in Koreans | 2 | Montelukast | Placebo | RCT | Crossover | Double | 18 | Not Applicable | 54 | X |
| 2 | A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (BREEZE-AD3) | 8 | Baricitinib | Placebo | RCT | Parallel Assignment | Double | 16 | 3 | 1500 | O |
| 3 | A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis (BREEZE-AD7) | 3 | Baricitinib | Placebo | RCT | Parallel Assignment | Double | 16 | 3 | 300 | O |
| 4 | Study of Baricitinib (LY3009104) in Adults With Moderate to Severe Atopic Dermatitis (BREEZE-AD2) | 4 | Baricitinib | Placebo | RCT | Parallel Assignment | Double | 16 | 3 | 750 | O |
| 5 | A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis | 4 | Upadacitinib | Placebo | RCT | Parallel Assignment | Double | 16 | 3 | 810 | X |
| 6 | Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-2) | 3 | PF-04965842 | Placebo | RCT | Parallel Assignment | Double | 12 | 3 | 375 | O |
| 7 | Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND) | 2 | PF-04965842 | Placebo | RCT | Parallel Assignment | Double | 12 | 3 | 2300 | O |
| 8 | Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare) | 5 | PF-04965842 Dupilumab | Placebo | RCT | Parallel Assignment | Double | 20 | 3 | 700 | O |
| 9 | Clinical trials of HH01 for adult atopic dermatitis | 2 | Hwanglyeonhaedok-tang | Placebo | RCT | Parallel Assignment | Double | 8 | 3 | 100 | X |
| Dermatologic agents | 10 | A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis | 7 | HY209 gel | Placebo | RCT | Parallel Assignment | Double | 4 | 1 | 56 | X |
| 11 | A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Adults With Atopic Dermatitis | 4 | PAC-14028 cream | Placebo | RCT | Parallel Assignment | Double | 8 | 2 | 192 | X |
| 12 | CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis | 2 | PAC-14028 cream | Placebo | RCT | Parallel Assignment | Double | 8 | 3 | 240 | O |
| 13 | A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Pediatric Atopic Dermatitis | 4 | PAC-14028 cream | Placebo | RCT | Parallel Assignment | Double | 4 | 1/2 | 56 | O |
| 14 | Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients | 2 | Jaungo | Placebo | RCT | Parallel Assignment | Double | 4 | 2 | 34 | O |
| 15 | Randomized, double-blind, multicenter, Parallel Assignment, placebo-controlled therapeutic exploratory study for the validation and safety of CP001 for patients with atopic dermatitis | 3 | CP001 | Placebo | RCT | Parallel Assignment | Double | 8 | 2 | 144 | O |
| 16 | Double-blind, randomized, placebo-controlled, Parallel Assignment, multicenter, Phase II clinical trial to assess the dose-response of HL009 in pediatric patients with mild and moderate atopic dermatitis. | 4 | HL-009 gel | Placebo | RCT | Parallel Assignment | Double | 8 | 2 | 219 | O |
| 17 | A 6-week, double-blind, randomized trial to evaluate the efficacy and safety of Elidel 1% cream for patients aged 2 to 11 years with a mild to moderate facial atopic dermatitis intolerant or dependent on topical corticosteroids , Placebo-controlled, 12-week multicenter trial consisting of a 6-week open-label trial | 2 | Elidel cream 1% | Placebo | RCT | Parallel Assignment | Double | 12 | 4 | 200 | O |
| injections | 18 | Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis | 1 | ADSTEM Inj. | None | None RCT | Parallel Assignment | None | 12 | 1 | 13 | O |
| 19 | Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) | 1 | FURESTEM-AD Inj. | None | None RCT | Parallel Assignment | None | 4 | 1/2a | 34 | O |
| 20 | Study of Autologous Total Immunoglobulin G Therapy for Atopic Dermatitis | 2 | Autologous immunoglobulin | Placebo | RCT | Parallel Assignment | Double | 8 | 2/3 | 51 | X |
| 21 | Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD) | 2 | FURESTEM-AD Inj. | Placebo | RCT | Parallel Assignment | Double | 12 | 3 | 194 | O |
| 22 | Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (ECZTRA 2) | 6 | Tralokinumab | Placebo | RCT | Parallel Assignment | Double | 16 | 3 | 780 | O |
| 23 | Open-label Study of Dupilumab (REGN668/ SAR231893) in Patients With Atopic Dermatitis | 1 | Dupilumab | None | None RCT | Parallel Assignment | None | 164 | 3 | 2000 | O |
| 24 | Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (CHRONOS) | 3 | Dupilumab | Placebo | RCT | Parallel Assignment | Double | 8 | 3 | 740 | O |
| 25 | A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis | 4 | Lebrikizumab | Placebo | RCT | Parallel Assignment | Double | 12 | 2 | 212 | O |
| 26 | Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 2) | 3 | Dupilumab | Placebo | RCT | Parallel Assignment | Double | 16 | 3 | 708 | O |
| 27 | A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis | 4 | Tezepelumab | Placebo | RCT | Parallel Assignment | Double | 16 | 2b | 300 | O |
| 28 | Ⅰ/Ⅱa clinical research to evaluate the safety and effectiveness of EBI-H (Auto-derived activated lymphocyte) for subacute above medium severity and chronic atopic dermatitis patients | 2 | EBI-H | None | RCT | Parallel Assignment | Double | 12 | 1/2a | 23 | O |